The association of matrix metalloproteinases (MMPs)-enzymes that disrupt the body's normal repair functions-with several diseases, including growing and invasive tumors, holds the tantalizing promise that their inhibiton might have therapeutic value. In Matrix Metalloproteinase Inhibitors in Cancer Therapy, cutting-edge investigators review the current status of the entire field, from the biology of MMPs through the current clinical studies. The authors include many leading scientists from pharmaceutical companies who present all the latest concepts and results on the preferred design strategies for MMP inhibitors, their molecular mechanisms, and their substrates. In addition, they fully describe their company's research effort on specific MMP inhibitors, detailing vanguard design strategies, their in vitro activity, the outcome of animal model studies and, where available, their toxicology, safety, and efficacy in human clinical trials. Comprehensive and state-of-the-art, Matrix Metalloproteinase Inhibitors offers basic and clinical investigators alike a richly informative summary of all the latest research on these powerful new drugs, and their high promise as emerging cancer therapeutics
CONTENT
1 Biology and Regulation of the Matrix Metalloproteinases -- 2 Substrate Specificity of MMPs -- 3 The Tissue Inhibitors of Metalloproteinases (TIMPs): Biology and Regulation -- 4 Matrix Metalloproteinases in Cancer -- 5 Hydroxamic Acid Matrix Metalloproteinase Inhibitors -- 6 Prinomastat: A Potent and Selective Matrix Metalloprotease Inhibitorโ{128}{148}Preclinical and Clinical Development for Oncology -- 7 A Potent Nonpeptidic Matrix Metalloproteinase Inhibitor: Discovery of BAY 12-9566 -- 8 D1927 and D2163: Novel Mercaptoamide Inhibitors of Matrix Metalloproteinases -- 9 Research on MMP Inhibitors with Unusual Scaffolds -- 10 Matrix Metalloproteinase Inhibitors: Therapeutic Applications Outside of Oncology
